Abstract
Type III Secretion Systems (T3SSs) are highly organized multi-protein nanomachines which translocate effector proteins from the bacterial cytosol directly into host cells. These systems are required for the pathogenesis of a wide array of Gram-negative bacterial pathogens, and thus have attracted attention as potential antibacterial drug targets. A decade of research has enabled the identification of natural products, conventional small molecule drug-like structures, and proteins that inhibit T3SSs. The mechanism(s) of action and molecular target(s) of the majority of these inhibitors remain to be determined. At the same time, structural biology methods are providing an increasingly detailed picture of the functional arrangement of the T3SS component proteins. The confluence of these two research areas may ultimately identify non-classical drug targets and facilitate the development of novel therapeutics.
Keywords: Type III secretion, virulence, Gram-negative bacteria, high-throughput screening, antibiotic drug discovery, T3SSs, Caminosides, Guadinomines, structural biology, benzanilides
Current Drug Targets
Title: The Type III Secretion System as a Source of Novel Antibacterial Drug Targets
Volume: 13 Issue: 3
Author(s): Toni Kline, Heather B. Felise, Sarah Sanowar and Samuel I. Miller
Affiliation:
Keywords: Type III secretion, virulence, Gram-negative bacteria, high-throughput screening, antibiotic drug discovery, T3SSs, Caminosides, Guadinomines, structural biology, benzanilides
Abstract: Type III Secretion Systems (T3SSs) are highly organized multi-protein nanomachines which translocate effector proteins from the bacterial cytosol directly into host cells. These systems are required for the pathogenesis of a wide array of Gram-negative bacterial pathogens, and thus have attracted attention as potential antibacterial drug targets. A decade of research has enabled the identification of natural products, conventional small molecule drug-like structures, and proteins that inhibit T3SSs. The mechanism(s) of action and molecular target(s) of the majority of these inhibitors remain to be determined. At the same time, structural biology methods are providing an increasingly detailed picture of the functional arrangement of the T3SS component proteins. The confluence of these two research areas may ultimately identify non-classical drug targets and facilitate the development of novel therapeutics.
Export Options
About this article
Cite this article as:
Kline Toni, B. Felise Heather, Sanowar Sarah and I. Miller Samuel, The Type III Secretion System as a Source of Novel Antibacterial Drug Targets, Current Drug Targets 2012; 13 (3) . https://dx.doi.org/10.2174/138945012799424642
DOI https://dx.doi.org/10.2174/138945012799424642 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Inhibition of 5-enolpyruvylshikimate-3-phosphate Synthase as a Model for Development of Novel Antimicrobials
Current Drug Targets Phytochemicals, Medicinal and Food Applications of Shatavari (Asparagus racemosus): An Updated Review
The Natural Products Journal Vanadium Complexes with Hydrazone or Thiosemicarbazone Ligands as Potential Anti-Mycobacterium tuberculosis Agents
Current Clinical Pharmacology Target Validation: Linking Target and Chemical Properties to Desired Product Profile
Current Topics in Medicinal Chemistry The β-Carbonic Anhydrases from Mycobacterium tuberculosis as Drug Targets
Current Pharmaceutical Design Microwave-assisted Single Step Cinnamic Acid Derivatization and Evaluation for Cytotoxic Potential
Current Pharmaceutical Biotechnology Tuberculous Lymphadenitis in Southern Italy: Clinical Aspects and Treatment Perspectives
Anti-Infective Agents Tartrate-Resistant Acid Phosphatase: A Target for Anti-Osteoporotic Chemotherapeutics
Current Enzyme Inhibition Advances in Synthesis and Medicinal Applications of Compounds Derived from Phthalimide
Current Organic Synthesis A Tour of Unsupervised Deep Learning for Medical Image Analysis
Current Medical Imaging Novel Urea/Thiourea Derivatives of Quinazolin-4(3H)-one: Design, Synthesis, Antimicrobial and Anti-TB Study
Letters in Drug Design & Discovery The TB Structural Genomics Consortium: Providing a Structural Foundation for Drug Discovery
Current Drug Targets - Infectious Disorders Transmucosal Delivery of Linagliptin for the Treatment of Type- 2 Diabetes Mellitus by Ultra-Thin Nanofibers
Current Drug Delivery Inhibition of Shikimate Kinase and Type II Dehydroquinase for Antibiotic Discovery: Structure-Based Design and Simulation Studies
Current Topics in Medicinal Chemistry Aqua Mediated Synthesis of Bio-active Compounds
Mini-Reviews in Medicinal Chemistry MenA Is a Promising Drug Target for Developing Novel Lead Molecules to Combat Mycobacterium tuberculosis
Medicinal Chemistry A Novel Finding: Macrophages Involved in Inflammation Participate in Acute Aortic Dissection Complicated with Acute Lung Injury
Current Molecular Medicine Selecting the Components for a Safe and Efficient Tuberculosis Subunit Vaccine - Recent Progress and Post-Genomic Insights
Current Pharmaceutical Biotechnology Heme Oxygenase-1 Dysregulation in the Brain: Implications for HIVAssociated Neurocognitive Disorders
Current HIV Research Galvez-Markov Network Transferability Indices: Review of Classic Theory and New Model for Perturbations in Metabolic Reactions
Current Drug Metabolism